Diagnosis of Parkinson’s: use of presynaptic dopaminergic imaging
Clinical Summary
Diagnosis of Parkinson's: use of presynaptic dopaminergic imaging
This is a brief clinical summary. It is supported by a series of Critically Appraised Topics (CATs), which are available on the UK Parkinson's Excellence Network online resource centre.
Introduction
The diagnosis of Parkinson's is primarily clinical. However, where there is uncertainty, presynaptic dopaminergic imaging may help establish the correct diagnosis. The main technique is FP-CIT SPECT, also known as DaTSCAN. This identifies the dopamine transporter.
Main clinical applications of DaTSCAN
When the clinical picture is incomplete, or there are pointers to a possible alternative diagnosis, or dual pathology may be present, perform a DaTSCAN when clinical uncertainty exists about the presence of dopamine deficiency as the cause of parkinsonism or tremor.
An abnormal scan is usually found in any process that reduces the density of the dopamine transporters, for example:
? n eurodegenerative disorders (such as idiopathic
Parkinson's, multiple system atrophy, progressive supranuclear palsy, dementia with Lewy bodies and corticobasal degeneration)
? n eurogenetic disorders (some spinocerebellar
ataxias such as SCA-2 and SCA-3, and Wilson's disease)
? c erebrovascular disease (if local basal ganglia
disruption, or damage to the pathways leading to the basal ganglia)
A normal scan is seen when the process does not affect the dopamine transporters, such as:
? e ssential tremor, dystonic tremor or other dystonia
(not all dystonia has tremor)
? d rug-induced parkinsonism and/or tremor
? functional parkinsonism and/or tremor
These are the typical clinical presentations and differential diagnoses in which DaTSCAN might be helpful:
? In asymmetric postural tremor: Parkinson's versus
essential or dystonic tremor.
? In unusual asymmetric tremor with functional
features: Parkinson's versus psychogenic parkinsonism.
? In dementia: Dementia with Lewy bodies versus
Alzheimer's or vascular dementia.
? P arkinson's versus parkinsonism secondary to drugs.
Interpretation of DaTSCAN
? In Parkinson's, putamen loss precedes caudate loss,
with asymmetry matching the clinical pattern.
? O ther neurodegenerative parkinsonism tends to
have more symmetrical deficits, but this distinction is not reliable in the individual case.
? C erebrovascular disease generally causes more
`punched-out' or `moth-eaten' deficits, compared with the smooth graded losses in other disorders.
Clinical Summary
? A false-negative scan result can occur early in the
development of Parkinson's.
? R eviewing the scan with a radiology or nuclear
medicine colleague may be helpful, if there is a definite mismatch between the clinical and imaging findings.
? If clinical suspicion of Parkinson's persists after a
negative or borderline initial scan, it is best to delay a repeat scan for about 12 to18 months, to allow assessment of change over time.
? P rognosis, and antiparkinsonian therapy response,
are not reliably predicted from the scan.
Preparing patients for DaTSCAN
? A djustment of existing medication is usually not
required.
? S top amphetamine-based drugs (eg appetite
suppressants).
? E vidence for interaction with MAOBI's (eg
selegiline, rasagiline) and SSRI's (eg fluoxetine, citalopram) is limited, so these can be maintained.
? T hyroid blocking is given in selected cases,
according to local protocols. This process is handled in the nuclear medicine department.
Clinical Summary
The UK Parkinson's Excellence Network is the driving force for improving Parkinson's care, connecting and equipping professionals to provide the services people affected by the condition want to see. The tools, education and data it provides are crucial for better services and professional development. The network links key professionals and people affected by Parkinson's, bringing new opportunities to learn from each other and work together for change. Visit .uk/excellencenetwork
Parkinson's UK is the operating name of the Parkinson's Disease Society of the United Kingdom. A charity registered in England and Wales (258197) and in Scotland (SC037554). ? Parkinson's UK 6/2017 (CS2734)
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- dopamine receptors and the kidney an overview of health and mdpi
- drugsforpsychosisandmood uniqueactionsatd3 d2 and d1 dopamine receptor
- d2 dopamine receptor regulation of learning sleep and plasticity
- what is the role of dopamine in reward hedonic impact reward brain
- effects and mechanisms of medicinal plants on dopamine reward system to
- dopamine d1 receptor s molecular pharmacology
- the physiology signaling and pharmacology of dopamine receptors
- dopamine receptors tocris bioscience
- the dopamine neuroleptic receptor cambridge university press assessment
- diagnosis of parkinson s use of presynaptic dopaminergic imaging
Related searches
- parkinson s disease timeline of progression
- parkinson s disease time of progression
- 5 stages of parkinson s disease
- final stages of parkinson s disease
- complete list of parkinson s symptoms
- criticism of plato s theory of forms
- signs of parkinson s progression
- 4 stages of parkinson s disease
- advanced symptoms of parkinson s disease
- stages of parkinson s disease
- product examples of maslow s hierarchy of needs
- end of life parkinson s symptoms